REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE Trial of RGX-202

By PR Newswire | June 02, 2025, 7:05 AM
  • Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial

ROCKVILLE, Md., June 2, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, the company's next-generation investigational gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will feature AFFINITY DUCHENNE principal investigator Aravindhan Veerapandiyan, M.D., Arkansas Children's Hospital.

Webcast details

Title: AFFINITY DUCHENNE® Trial of RGX-202: Phase I/II Interim Functional Data

Date/Time: Thursday, June 5, 2025, at 8:00 a.m. EDT 

Access: The live webcast can be accessed here and in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.REGENXBIO.com.

Contacts:

Dana Cormack

Corporate Communications

[email protected] 

Investors:

George E. MacDougall

Investor Relations

[email protected]

(PRNewsfoto/REGENXBIO Inc.)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-webcast-discussing-interim-functional-data-from-the-phase-iii-affinity-duchenne-trial-of-rgx-202-302470286.html

SOURCE REGENXBIO Inc.

Mentioned In This Article

Latest News

Jun-02
May-20
May-19
May-14
May-14
May-13
May-13
May-13
May-12
May-12
May-12
May-09
May-08
May-06
May-05